PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells

详细信息    查看全文

• 作者：Gilles Buchwalter¹ ; ⁴ ; Michele M. Hickey² ; ⁴ ; Anne Cromer² ; Laura M. Selfors² ; Ruwanthi N. Gunawardane² ; Jason Frishman¹ ; Rinath Jeselsohn¹ ; Elgene Lim¹ ; David Chi¹ ; Xiaoyong Fu³ ; Rachel Schiff³ ; Myles Brown¹ ; ^{myles_brown@dfci.harvard.edu} ; Joan S. Brugge² ; ^{joan_brugge@hms.harvard.edu}
• 刊名：Cancer Cell
• 出版年：2013
• 出版时间：10 June, 2013
• 年：2013
• 卷：23
• 期：6
• 页码：753-767
• 全文大小：2881 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Breast cancer is a heterogeneous disease and can be classified based on gene expression profiles that reflect distinct epithelial subtypes. We identify prostate-derived ETS factor (PDEF) as a mediator of mammary luminal epithelial lineage-specific gene expression and as a factor required for tumorigenesis in a subset of breast cancers. PDEF levels strongly correlate with estrogen receptor (ER)-positive luminal breast cancer, and PDEF transcription is inversely regulated by ER and GATA3. Furthermore, PDEF is essential for luminal breast cancer cell survival and is required in models of endocrine resistance. These results offer insights into the function of this ETS factor that are clinically relevant and may be of therapeutic value for patients with breast cancer treated with endocrine therapy.